AstraZeneca's Fasenra has been cleared for use by the NHS in England as an add-on treatment for the rare autoimmune disease ...

Columnist Caroline Gainer finds the mantra "Stay busy. Be useful." to be good guiding words for living with COPD.

GSK ha anunciado hoy que la Agencia Europea de Medicamentos (EMA) ha aceptado revisar su solicitud de ampliar el uso de mepolizumab, un anticuerpo monoclonal que actúa sobre la interleucina 5 (IL-5), ...

GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its current portfolio. While the company’s total sales in this period totalled £8bn ...

GSK eleva su previsión para 2025 tras un salto en beneficios por fuertes ventas de medicamentos para VIH y cáncer ...

Nucala (mepolizumab) muestra una reducción estadísticamente significativa y clínicamente relevante en las exacerbaciones de EPOC, según los resultados positivos del ensayo MATINEE publicados en la ...

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new medicines, including a promising candidate for a chronic lung condition, the ...

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) mainly to itself since June 2019, but GlaxoSmithKline’s Nucala is ...

The FDA has approved mepolizumab (Nucala), a biologic COPD treatment designed to reduce flare-ups. Learn how it works and who it might help.